Study S000393

The Medically Reproducing Bariatric Surgery (MRB) II Study: SEMAGLUTIDE Followed by OPTIFAST in Veterans With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06363747
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 50
Start: 2024-06-24
Primary completion: 2025-11-03
Lead sponsor: Durham VA Medical Center
Conditions: Type 2 Diabetes; Obesity
Interventions: OTHER:Very Low Calorie Diet
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Glycemic Control [baseline, week 12, week 24, week 48]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010163	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Andreadis P, Diabetes, obesity & metabolism	2018	Systematic review	PMID 29756388 DOI	registry reference BACKGROUND:29756388
R0022060	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27295427 DOI	registry reference BACKGROUND:27295427
R0016788	Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diamant M, Diabetes care	2014	Randomized trial	PMID 25011946 DOI	registry reference BACKGROUND:25011946